In a groundbreaking development for cardiac healthcare, two wearable monitors have received FDA approval, promising to significantly enhance the accuracy of continuous electrocardiogram (ECG) monitoring. Wellysis, a company that emerged from Samsung in 2019, and Swiss-based SmartCardia have unveiled their regulatory triumphs, ushering in a new era of precision in cardiac health monitoring.
Wellysis' S-Patch Ex, which gained CE mark authorization in 2021, has already made waves across more than a dozen locations, including various European countries. This lightweight, waterproof patch is equipped with Samsung's cutting-edge Bio Processor chip and can be worn on the user's chest for up to 72 hours. It seamlessly transmits crucial heart electrical data to a smartphone, smartwatch, or tablet app, providing users with real-time results and allowing them to track their progress. Additionally, the data is accessible through a cloud-based web interface, enabling clinicians to delve into raw ECG, heart rate, and symptom data.
Furthermore, Wellysis has announced its plans to introduce the S-Patch Ex in the U.S. this month, with strategic collaborations in place with service and platform providers. This move is poised to usher in a new era of accessibility for advanced cardiac monitoring technologies.
Meanwhile, SmartCardia's 7L patch and cloud-based platform have also received FDA approval, marking a significant milestone in cardiac health monitoring. This innovative device boasts an impressive seven leads, providing a more comprehensive view of heart activity compared to its single-lead counterparts.The platform is equipped to issue visual and audio alarms in the event of abnormal readings, providing an invaluable tool for both patients and healthcare providers.
SmartCardia's CTO, Francisco Rincon, emphasized the real-time nature of the monitoring system, stating, "100% of the ECG data, not just events, is transmitted in real-time, and the automated analysis is performed throughout the entire signal." This full-disclosure analysis ensures highly accurate arrhythmia detection, while the user-friendly cloud platform allows clinicians to swiftly view and analyze ECG data at any given moment.
The combined efforts of Wellysis and SmartCardia represent a major leap forward in cardiac healthcare, offering clinicians a comprehensive view of patients' cardiac activity over extended periods. These advancements are set to revolutionize the detection of conditions such as atrial fibrillation and other heart disorders. With these wearable monitors now approved by the FDA, the future of cardiac health monitoring looks brighter than ever before.
